Search Team

Search by Last Name
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
 

Background

Mr. Singer, a renowned life sciences industry leader and acclaimed trial attorney, heads the firm’s life sciences litigation practice. Whether working as lead trial counsel for his clients or as part of a trial or litigation team, Mr. Singer handles all aspects of litigation, including leading jury and bench trials, trying cases to administrative and arbitration panels and conducting briefing and arguments before the Courts of Appeals. Mr. Singer is annually named one of the nation’s finest life sciences trial attorneys, and is an expert in proceedings under the Hatch-Waxman Act. His clients consistently praise his innovative and ground-breaking work in cases like Mayo Collaborative Services, et al v. Prometheus Labs, In re Cyclobenzaprine and Allergan v. Barr Labs. In addition to his courtroom work, Mr. Singer teaches life sciences trial and patent practice courses around the country.

Education

J.D., University of Chicago Law School 1992
with honors


A.B., Dartmouth College 1986
Chemistry
Daniel Webster Scholar

Admissions

  • California 1997
  • Minnesota 1998
  • Supreme Court of the United States
  • U.S. Court of Appeals for the Federal Circuit

Other Distinctions

Mr. Singer has received numerous awards for his courtroom work, including:

  • IAM Patent 1000, Intellectual Asset Management (2013, 2016)
  • Best Lawyer(R) in America for Patent Litigation (2016)
  • “IP Star,” Managing Intellectual Property (2013-2016)
  • Leader in IP litigation, Chambers USA (2007 – 2015)
  • Life Sciences MVP, Law 360 (2013)
  • Lawdragon 500 Leading Lawyers in America (2013)
  • “Life Science Star”, LMG Life Sciences (2012-13)
  • Super Lawyer, Minnesota Law & Politics, (2006, 2010-13)
  • Appellate MVP, Law 360 (2012)
  • “Best in Bar,” Minneapolis St. Paul Business Journal (2012)
  • Litigator of the Week, American Lawyer (8/25/2011, 3/23/2012, 6/9/2016)
  • Attorney of the Year, Minnesota Lawyer (2007, 2009, 2012)
  • Intellectual Property Advisory Board, Law 360 (2011)
  • IAM Life Sciences 250, Intellectual Asset Management (2010)
  • Client Service All Star, BTI (2006)

Course faculty member, “Biotechnology: Patent Prosecution, Licensing, Litigation, and Hatch-Waxman,” Patent Resources Group, Inc.

Featured Video
A Conversation with Life Science Litigator Jonathan Singer

Experience

view all

What's trending with Jon

Filter by
News
November 21, 2016
Fish & Richardson Announces Six Principals Named 2016 “Life Science Stars” by LMG Life Sciences
Press Releases
News
July 1, 2016
Fish & Richardson Named One of 24 Most Loved Law Firms by General Counsel; One of 10 Firms GCs Love for Pharma Work
Press Releases
News
June 7, 2016
Fish & Richardson Obtains Reversal of $200 Million Patent Verdict Against Gilead After Merck’s “Pervasive Pattern of Misconduct”
Press Release
News
June 29, 2016
Fish Receives Top Tier 1 National Rankings in Patent Prosecution and Patent Litigation from The Legal 500
Press Releases
News
June 15, 2016
Fish & Richardson Named to IAM Patent 1000 for National Patent Litigation and Prosecution Practices
Press Releases
News
June 8, 2016
Fish Receives Top “Band 1” National Rankings for Intellectual Property and ITC Practices in Chambers USA 2016
Press Releases
News
March 23, 2016
Fish & Richardson Awarded “Milestone Case of the Year” at Managing Intellectual Property’s North America Awards 2016
Press Release
News
December 17, 2015
Two Principals Named Litigation Trailblazers for 2015 by The National Law Journal
Press Releases
News
November 19, 2015
Fish & Richardson Named to NLJ 2015 Appellate Hot List; Marks Fifth Year on Prestigious List
Press Releases
News
November 18, 2015
Principal Jon Singer named 2015 Life Sciences MVP by Law360
Press Releases
Media Coverage
IP Updates
News
November 10, 2015
Fish & Richardson Announces Five Principals Named 2015 "Life Sciences Stars" by LMG Life Sciences
Press Releases
News
August 6, 2015
Fish & Richardson Affirms Patent Infringement Win for Allergan Over Generic LUMIGAN® 0.01% at the Federal Circuit
Press Releases
load more topics